Ordenar

Buscar

Barra de búsqueda
01/06/2026 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
Powles, T, van der Heijden, MS, Bedke, J, Valderrama, BP, Kikuchi, E, Galsky, MD, Loriot, Y, Iyer, G, Yu, EY, Hoffman-Censits, J, Mar, N, Vulsteke, C, Sridhar, SS, Maroto-Rey, JP, Park, SH, Moreno, BH, Lichfield, J, Yu, XS, Wirtz, H, Gupta, S. Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.4507. PMID:. IF:41.900(Q1/1D).
01/06/2026 Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.
Portu, M, Sanz-Beltran, J, Pellicer, A, Navarro, B, Monleon, AR, Capdevila, P, Tallafigo, FL, Moran, T, Catot, S, Munoz, SP, Arriola, E, Sanchez, A, Osorio, K, Muñoz, A, Isla, D, Guarner, B, Piedra, A, Recio, SM, Barba, A, Majem, M. Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8107. PMID:. IF:41.900(Q1/1D).
01/06/2026 Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
Forster, MD, Forget, F, Murillo, SM, García-Fructuoso, I, Ibrahim, NK, Marathe, O, Kristensen, CA, Laban, S, Metcalf, R, Majem, M, Peguero, JA, Wildiers, H, Marmé, F, Brana, I, Mueller, C, Brignone, C, Triebel, F. Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.2569. PMID:. IF:41.900(Q1/1D).
01/06/2026 Clinical impact and molecular profiling of PTEN loss and TMPRSS2:ERG fusion in metastatic hormone-sensitive prostate cancer.
Crous, C, de Herreros, MG, Torras, OR, Jimenez, N, Ferrer-Mileo, L, Garcia-Esteve, S, Rodriguez, L, Altamirano, M, Salinas, B, Cobo-Lopez, S, Fernandez-Mañas, L, Duran, MAC, Pous, AF, Chirivella, I, Figols, M, Costa, SC, Rodriguez-Vida, A, Anguera, G, González, NS, Mellado, B. Clinical impact and molecular profiling of PTEN loss and TMPRSS2:ERG fusion in metastatic hormone-sensitive prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5101. PMID:. IF:41.900(Q1/1D).